Chondrosarcoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Chondrosarcoma – Pipeline Review, H1 2017’, provides an overview of the Chondrosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chondrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chondrosarcoma

The report reviews pipeline therapeutics for Chondrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chondrosarcoma therapeutics and enlists all their major and minor projects

The report assesses Chondrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chondrosarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chondrosarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chondrosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Agios Pharmaceuticals Inc 20

Celgene Corp 20

CytRx Corp 21

Daiichi Sankyo Company Ltd 21

EpiZyme Inc 22

Horizon Pharma Plc 22

Karyopharm Therapeutics Inc 23

Merck & Co Inc 23

Novartis AG 24

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Chondrosarcoma - Overview 6

Chondrosarcoma - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Chondrosarcoma - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Chondrosarcoma - Companies Involved in Therapeutics Development 20

Agios Pharmaceuticals Inc 20

Celgene Corp 20

CytRx Corp 21

Daiichi Sankyo Company Ltd 21

EpiZyme Inc 22

Horizon Pharma Plc 22

Karyopharm Therapeutics Inc 23

Merck & Co Inc 23

Novartis AG 24

Pfizer Inc 24

Chondrosarcoma - Drug Profiles 25

aldoxorubicin hydrochloride - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

axitinib - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

DS-1001 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

enasidenib mesylate - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

galarmin - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

interferon gamma-1b - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

ivosidenib - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

ligerin - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

pazopanib hydrochloride - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

pembrolizumab - Drug Profile 76

R&D Progress 77

selinexor - Drug Profile 128

Product Description 128

Mechanism Of Action 128

R&D Progress 128

sirolimus - Drug Profile 149

Product Description 149

Mechanism Of Action 149

R&D Progress 149

tazemetostat - Drug Profile 151

Product Description 151

Mechanism Of Action 151

R&D Progress 151

Chondrosarcoma - Dormant Projects 160

Chondrosarcoma - Discontinued Products 161

Chondrosarcoma - Product Development Milestones 162

Featured News & Press Releases 162

Nov 18, 2016: Agios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma 162

Appendix 164

Methodology 164

Coverage 164

Secondary Research 164

Primary Research 164

Expert Panel Validation 164

Contact Us 164

Disclaimer 165

List of Tables

List of Tables

Number of Products under Development for Chondrosarcoma, H1 2017 7

Number of Products under Development by Companies, H1 2017 8

Number of Products under Development by Universities/Institutes, H1 2017 9

Products under Development by Companies, H1 2017 10

Products under Development by Universities/Institutes, H1 2017 11

Number of Products by Stage and Target, H1 2017 13

Number of Products by Stage and Mechanism of Action, H1 2017 15

Number of Products by Stage and Route of Administration, H1 2017 17

Number of Products by Stage and Molecule Type, H1 2017 19

Chondrosarcoma – Pipeline by Agios Pharmaceuticals Inc, H1 2017 20

Chondrosarcoma – Pipeline by Celgene Corp, H1 2017 20

Chondrosarcoma – Pipeline by CytRx Corp, H1 2017 21

Chondrosarcoma – Pipeline by Daiichi Sankyo Company Ltd, H1 2017 21

Chondrosarcoma – Pipeline by EpiZyme Inc, H1 2017 22

Chondrosarcoma – Pipeline by Horizon Pharma Plc, H1 2017 22

Chondrosarcoma – Pipeline by Karyopharm Therapeutics Inc, H1 2017 23

Chondrosarcoma – Pipeline by Merck & Co Inc, H1 2017 23

Chondrosarcoma – Pipeline by Novartis AG, H1 2017 24

Chondrosarcoma – Pipeline by Pfizer Inc, H1 2017 24

Chondrosarcoma – Dormant Projects, H1 2017 160

Chondrosarcoma – Discontinued Products, H1 2017 161

List of Figures

List of Figures

Number of Products under Development for Chondrosarcoma, H1 2017 7

Number of Products under Development by Companies, H1 2017 8

Number of Products by Top 10 Targets, H1 2017 12

Number of Products by Stage and Top 10 Targets, H1 2017 12

Number of Products by Top 10 Mechanism of Actions, H1 2017 14

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 14

Number of Products by Routes of Administration, H1 2017 16

Number of Products by Stage and Routes of Administration, H1 2017 16

Number of Products by Molecule Types, H1 2017 18

Number of Products by Stage and Molecule Types, H1 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports